Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial†

Phase I study of cetuximab (CET) in combination with 5-fluorouracil (5-FU), cisplatin (CP), and radiotherapy (RT) in patients with locally advanced squamous cell anal carcinoma (LAAC)

(2017) L. O. Olivatto et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictive factors of early and late local toxicities in anal cancer treated by radiotherapy in combination with or without chemotherapy.

(2017) Jerome Doyen et al.   JOURNAL OF CLINICAL ONCOLOGY

Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial

(2013) Roger D James et al.   LANCET ONCOLOGY

EGFR and K-ras gene mutation status in squamous cell anal carcinoma: a role for concurrent radiation and EGFR inhibitors?

(2012) A Paliga et al.   BRITISH JOURNAL OF CANCER

Long-Term Update of US GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil/Mitomycin Versus Fluorouracil/Cisplatin

(2012) Leonard L. Gunderson et al.   JOURNAL OF CLINICAL ONCOLOGY

Induction Chemotherapy and Dose Intensification of the Radiation Boost in Locally Advanced Anal Canal Carcinoma: Final Analysis of the Randomized UNICANCER ACCORD 03 Trial

(2012) Didier Peiffert et al.   JOURNAL OF CLINICAL ONCOLOGY

IMRT for locally advanced anal cancer: clinical experience of the Montpellier Cancer Center

(2012) Sabine Vieillot et al.   Radiation Oncology

Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal

(2011) Jose G. Bazan et al.   CANCER

Randomized Phase II Study of Pemetrexed, Carboplatin, and Thoracic Radiation With or Without Cetuximab in Patients With Locally Advanced Unresectable Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 30407

(2011) Ramaswamy Govindan et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non–Small-Cell Lung Cancer: RTOG 0324

(2011) George R. Blumenschein et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation ofSmad4(Dpc4)Immunostaining With Pattern of Disease Progression

(2011) Christopher H. Crane et al.   JOURNAL OF CLINICAL ONCOLOGY

Cetuximab in Combination With Chemoradiotherapy Before Surgery in Patients With Resectable, Locally Advanced Esophageal Carcinoma: A Prospective, Multicenter Phase IB/II Trial (SAKK 75/06)

(2011) Thomas Ruhstaller et al.   JOURNAL OF CLINICAL ONCOLOGY

Mitomycin-C– or Cisplatin-Based Chemoradiotherapy for Anal Canal Carcinoma: Long-Term Results

(2010) Luis O. Olivatto et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Dose-Painted Intensity-Modulated Radiation Therapy for Anal Cancer: A Multi-Institutional Report of Acute Toxicity and Response to Therapy

(2010) Lisa A. Kachnic et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Induction Therapy for Poor-Prognosis Anal Canal Carcinoma: A Phase II Study of the Cancer and Leukemia Group B (CALGB 9281)

(2008) Neal J. Meropol et al.   JOURNAL OF CLINICAL ONCOLOGY